Drug Trial Radar · NCT03990688
A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 3, 2019
Primary completion
Sep 9, 2020
Study completion Sep 21, 2020
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
AK3280 is being developed to further improve the long-term efficacy and tolerability of treatment options for patients with fibrotic disorders.This study will evaluate the effect of AK3280 treatment on renal function and safety, and the PK of AK3280 compared with placebo in healthy subjects.
Conditions
- Healthy
Interventions
AK3280Drug
Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Directly measured absolute glomerular filtration rate (mGFR) results.Time frame: Days -1, 7, and 14.
- Change from baseline mGFR results.Time frame: Days 7 and 14.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CTC Clinical Trial Consultants AB
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.